Lisa Cook sues Trump over firing attempt, emergency hearing set
Haleon plc (LSE/NYSE:HLN), a global leader in consumer health, declared today the annual update of its Euro Medium Term Note (EMTN) Programme. The company, known for brands like Advil and Centrum, confirmed that the listing particulars dated May 7, 2025, for its £10 billion EMTN Programme, have been published. This programme is guaranteed by Haleon and involves Haleon UK Capital plc and Haleon Netherlands Capital B.V.
The listing particulars are now available for public inspection and can be downloaded from the company’s website. The document provides essential information for investors and is part of Haleon’s routine financial disclosures. The update is a standard practice for such financial instruments, which are used by companies to raise capital in international markets.
Haleon, which operates in various health-related sectors including Oral Health, Pain Relief, and Vitamins, Minerals and Supplements (VMS), has a strong presence in the consumer health industry. The company’s commitment to "deliver better everyday health with humanity" is backed by a portfolio of well-established products that are trusted by consumers worldwide.
The EMTN Programme plays a significant role in Haleon’s capital structure and financial strategy. The programme allows the company to issue debt securities over time, providing flexibility in financing its operations and growth initiatives.
Investors and media looking for further information can reach out to Haleon’s investor relations and corporate media contacts provided in the press release statement. The company has made it clear that the information contained in the listing particulars is intended for residents of particular countries and must be used in accordance with the specified guidelines.
This announcement is based on a press release statement from Haleon plc and does not constitute financial advice or an endorsement of the company’s financial products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.